These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 1835223)

  • 21. Review of dalbavancin, a novel semisynthetic lipoglycopeptide.
    Kim A; Kuti JL; Nicolau DP
    Expert Opin Investig Drugs; 2007 May; 16(5):717-33. PubMed ID: 17461743
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Teicoplanin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.
    Campoli-Richards DM; Brogden RN; Faulds D
    Drugs; 1990 Sep; 40(3):449-86. PubMed ID: 2146108
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The use of a new glycopeptide antibiotic, teicoplanin, in the treatment of bacterial endocarditis.
    Webster A; Wilson AP; Williams AH; Treasure T; Grüneberg RN
    Postgrad Med J; 1987 Aug; 63(742):621-4. PubMed ID: 2962071
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study.
    Cepeda JA; Whitehouse T; Cooper B; Hails J; Jones K; Kwaku F; Taylor L; Hayman S; Shaw S; Kibbler C; Shulman R; Singer M; Wilson AP
    J Antimicrob Chemother; 2004 Feb; 53(2):345-55. PubMed ID: 14711840
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical efficacy and safety of teicoplanin in the treatment of gram-positive infections.
    Kempf P; Pompetzki H; Oppermann A; Wittenberger R; Siebert J; Fell JJ; Dieterich HA
    Infection; 1989; 17(3):177-81. PubMed ID: 2525529
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
    Guskey MT; Tsuji BT
    Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of skin, skin structure, bone, and joint infections with ceftazidime.
    Gentry LO
    Am J Med; 1985 Aug; 79(2A):67-74. PubMed ID: 3895921
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Teicoplanin.
    Shea KW; Cunha BA
    Med Clin North Am; 1995 Jul; 79(4):833-44. PubMed ID: 7791426
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bacterial endocarditis treated with intramuscular teicoplanin.
    Chauhan S; D'Cruz S; Sachdev A; Singh R
    Singapore Med J; 2007 Sep; 48(9):e248-9. PubMed ID: 17728952
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Teicoplanin in the therapy of staphylococcal neuroshunt infections.
    Maserati R; Cruciani M; Azzini M; Carnevale C; Suter F; Concia E
    Int J Clin Pharmacol Res; 1987; 7(3):207-13. PubMed ID: 2954919
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of dalbavancin in skin and soft tissue infections.
    Bassetti M; Peghin M; Carnelutti A; Righi E
    Curr Opin Infect Dis; 2018 Apr; 31(2):141-147. PubMed ID: 29298166
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of teicoplanin in gram-positive pulmonary infections.
    Sanduzzi A; Nani E; Sarno M; Vatrella A; Parrella R; Mattiello A
    J Chemother; 1991 Jan; 3 Suppl 1():224-6. PubMed ID: 12041771
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Evaluation of clinical evidence for dalbavancin].
    Rodríguez-Pardo D
    Enferm Infecc Microbiol Clin; 2017 Jan; 35 Suppl 1():33-37. PubMed ID: 28129819
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of outpatient parenteral antibiotic therapy in the treatment of community acquired skin and soft tissue infections in Singapore.
    Chan M; Ooi CK; Wong J; Zhong L; Lye D
    BMC Infect Dis; 2017 Jul; 17(1):474. PubMed ID: 28683717
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Teicoplanin: a new glycopeptide antibiotic complex.
    Babul N; Pasko M
    Drug Intell Clin Pharm; 1988 Mar; 22(3):218-26. PubMed ID: 2966729
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Infections due to gram-positive organisms in children: possible role for teicoplanin.
    Dagan R; Einhorn M; Howard CB; Williams AH
    J Antimicrob Chemother; 1991 Apr; 27 Suppl B():37-41. PubMed ID: 1829075
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activity of teicoplanin in localized experimental infections in rats.
    Arioli V; Berti M; Candiani G
    J Hosp Infect; 1986 Mar; 7 Suppl A():91-9. PubMed ID: 2871103
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of intraventricular teicoplanin for the treatment of neurosurgical shunt infections.
    Cruciani M; Navarra A; Di Perri G; Andreoni M; Danzi MC; Concia E; Bassetti D
    Clin Infect Dis; 1992 Aug; 15(2):285-9. PubMed ID: 1387805
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of femoral intra-arterial administration of teicoplanin in gram-positive diabetic foot infections.
    Dorigo B; Cameli AM; Trapani M; Raspanti D; Torri M; Mosconi G
    Angiology; 1995 Dec; 46(12):1115-22. PubMed ID: 7495317
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dalbavancin and Oritavancin: An Innovative Approach to the Treatment of Gram-Positive Infections.
    Roberts KD; Sulaiman RM; Rybak MJ
    Pharmacotherapy; 2015 Oct; 35(10):935-48. PubMed ID: 26497480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.